<div id="readability-page-1"><p>Norges Bank purchased a new position in shares of  Organon &amp; Co. (NYSE:OGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,043,153 shares of the company's stock, valued at approximately $19,778,000. Norges Bank owned about 0.79% of Organon &amp; Co. as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Organon &amp; Co.</strong> alerts:</span></p></div><ul><li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li></ul><p>Other hedge funds and other institutional investors have also made changes to their positions in the company. Ransom Advisory Ltd bought a new position in shares of  Organon &amp; Co. during the first quarter worth approximately $32,000.  Hanson &amp; Doremus Investment Management bought a new stake in shares of  Organon &amp; Co. in the second quarter valued at approximately $26,000.  Hantz Financial Services Inc. lifted its position in  Organon &amp; Co. by 293.8% during the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company's stock worth $26,000 after purchasing an additional 1,995 shares during the period.  Brooklyn Investment Group grew its stake in  Organon &amp; Co. by 1,012.3% during the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock worth $46,000 after buying an additional 2,794 shares in the last quarter.  Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in  Organon &amp; Co. in the first quarter valued at approximately $51,000. 77.43% of the stock is owned by institutional investors. </p><h2>Analyst Ratings Changes</h2><p>A number of equities analysts recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating for the company in a research report on Tuesday, November 11th. JPMorgan Chase &amp; Co. reduced their price objective on shares of Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a research note on Wednesday, October 8th. Finally, Piper Sandler cut Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 target price on the stock. in a report on Monday, October 27th. One equities research analyst  has rated the stock with a Strong Buy rating, one  has given a Buy rating, two have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $12.50.</p><ul><li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li></ul><p><b>Get Our Latest Report on OGN</b></p><h2>Organon &amp; Co. Stock Up 2.3%</h2><p>Organon &amp; Co. stock opened at $7.30 on Tuesday. The firm has a 50 day moving average price of $8.22 and a 200-day moving average price of $9.21. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. Organon &amp; Co. has a twelve month low of $6.18 and a twelve month high of $17.23. The company has a market capitalization of $1.90 billion, a P/E ratio of 3.80, a P/E/G ratio of 1.53 and a beta of 0.57. </p><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. Organon &amp; Co. had a return on equity of 143.47% and a net margin of 7.95%.The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share.  As a group, equities analysts predict that  Organon &amp; Co. will post 3.68 EPS for the current year. </p><h2>Organon &amp; Co. Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 20th. Organon &amp; Co.'s dividend payout ratio  is currently 4.17%. </p><h2>About Organon &amp; Co.</h2> (Free Report)<p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Organon &amp; Co.</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>How to Buy Cheap Stocks Step by Step</li><li>3 Stocks Most Likely to Split in 2026</li><li>Asset Allocation Strategies in Volatile Markets</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2><p>Before you consider Organon &amp; Co., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p><p>While Organon &amp; Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Norges Bank acquired 2,043,153 shares of Organon & Co., valued at $19.78 million, during Q2. The stock has mixed analyst ratings, with a consensus target price of $12.50. Organon & Co. reported Q3 earnings of $1.01 per share, beating estimates. The company announced a quarterly dividend of $0.02 per share, payable on December 11th.</p>

Norges Bank Takes $19.78 Million Position in Organon & Co. $OGN